OLMESARTAN MEDOXOMIL/AMLODIPINA FLOMI 20mg / 5mg film-coated tablets medication leaflet

C09DB02 olmesartan + amlodipine • Cardiovascular system | Angiotensin II receptor blockers (ARBs), combinations | Angiotensin ii receptor blockers (arbs) and calcium channel blockers

This combination of olmesartan and amlodipine is used for the treatment of hypertension, particularly in patients requiring combination therapy to control blood pressure. Olmesartan blocks angiotensin II receptors, while amlodipine relaxes blood vessels by blocking calcium channels.

The medication is taken orally, usually once daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and not discontinue treatment without consulting their doctor.

Patients should be aware of potential side effects, such as dizziness, edema, or headaches. It is important to inform the doctor of any unusual symptoms.

Common side effects include dizziness, edema, headaches, and fatigue. In rare cases, severe reactions such as kidney failure or allergic reactions may occur. Patients should be informed of these risks before starting treatment.

General data about OLMESARTAN MEDOXOMIL/AMLODIPINA FLOMI 20mg / 5mg

Substance: olmesartan + amlodipine

Date of last drug list: 01-06-2021

Commercial code: W67579001

Concentration: 20mg / 5mg

Pharmaceutical form: film-coated tablets

Quantity: 14

Product type: generic

Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Marketing authorisation

Manufacturer: GENEPHARM S.A. - GRECIA

Holder: GENEPHARM S.A. - GRECIA

Number: 11875/2019/01

Shelf life: 2 years

Concentrations available for olmesartan + amlodipine

20mg/5mg, 40mg/10mg, 40mg/5mg

Combinations with other substances